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Abstract
Objective: To evaluate the impact of COVID-19 pandemic migitation measures on of
ST-elevation myocardial infarction (STEMI) care.
Background: We previously reported a 38% decline in cardiac catheterization activations during the early phase of the COVID-19 pandemic mitigation measures. This
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study extends our early observations using a larger sample of STEMI programs representative of different US regions with the inclusion of more contemporary data.
Methods: Data from 18 hospitals or healthcare systems in the US from January 2019
to April 2020 were collecting including number activations for STEMI, the number of
activations leading to angiography and primary percutaneous coronary intervention
(PPCI), and average door to balloon (D2B) times. Two periods, January 2019–
February 2020 and March–April 2020, were defined to represent periods before
(BC) and after (AC) initiation of pandemic mitigation measures, respectively. A generalized estimating equations approach was used to estimate the change in response
variables at AC from BC.
Results: Compared to BC, the AC period was characterized by a marked reduction in
the number of activations for STEMI (29%, 95% CI:18–38, p < .001), number of activations leading to angiography (34%, 95% CI: 12–50, p = .005) and number of activations leading to PPCI (20%, 95% CI: 11–27, p < .001). A decline in STEMI activations
drove the reductions in angiography and PPCI volumes. Relative to BC, the D2B
times in the AC period increased on average by 20%, 95%CI (−0.2 to 44, p = .05).
Conclusions: The COVID-19 Pandemic has adversely affected many aspects of STEMI
care, including timely access to the cardiac catheterization laboratory for PPCI.
KEYWORDS
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The coronavirus 2019 (COVID-19) pandemic has significantly
1,2

impacted healthcare delivery around the globe.

|

METHODS

A total of 18 sites representing PPCI hospitals and healthcare systems

To preserve hospital

across the US were included in the study (Table S1 and Figure S1). In

beds and intensive care unit capacity, elective cardiovascular proce-

this study, March 1, 2020, was identified as the date when US medical

dures have been canceled or postponed, and access to in-person out-

operations were significantly affected. It was also the day that

patient clinics have been severely restricted.3

New York City, the current epicenter of the US pandemic, reported its

An unexpected and troublesome decline in the number of

first COVID-19 case through social distancing was not recommended

patients seeking medical care for cardiovascular emergencies has been

by the federal government until March 15th. Therefore, we identified

reported during the early phase of the pandemic.4,5 Concomitantly,

two periods before and after March 1, 2020, and label them as BC

the number of patients suffering cardiac arrest at home has signifi-

and AC, accordingly. The BC period encompasses the 14 months from

6,7

cantly increased in areas most affected by COVID-19.

Taken

together, these observations suggest that many patients with acute

January 1, 2019, to February 29, 2020. The AC period includes March
and April of 2020.

cardiovascular conditions may be circumventing needed medical care.

Data on monthly volumes of cardiac catheterization laboratory

We previously reported a 38% decline in cardiac catheterization labo-

activations for STEMI, cardiac catheterization laboratory activations

ratory activations for ST-segment elevation myocardial infarction

leading to angiography, and PPCI were collected. In addition, monthly

(STEMI) in 9 high-volume STEMI centers in the early phase of the

mean door-to-balloon (D2B) times (in minutes) were collected for

Pandemic.8 The purpose of this investigation is to extend and expand

each study site. Since COVID-19 cases in the US initially clustered in

on our early observations by (a) including 18 hospitals or healthcare

the Tri-state area in the Northeast of the US, we grouped STEMI pro-

systems representative of different regions of the US with varying

grams into four geographic regions (Northeast, South, West, and Mid-

COVID-19 incidence rates, (2) analyzing other metrics relevant to

west) to account for potential differential effects according to

STEMI care including the number of cardiac catheterization laboratory

COVID-19 disease burden and testing (Table S2).

activations leading to angiography and primary percutaneous coronary

Continuous study variables were summarized using median and

intervention (PPCI), and door to balloon (D2B) times, and (3) continua-

interquartile ranges (median Q1, Q3). For each response variable, the

tion of our analysis of STEMI decline into April 2020, including a com-

change in volumes at AC from BC were estimated using a generalized

parison with March 2020 to assess novel trends.

estimating

equations

approach

to

account

for

within-site

3
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dependencies. Poisson models were used for variables reflecting pro-
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cedural volumes (STEMI, angiography, and PCI), and a Gaussian distribution was used to estimate changes in the door to balloon times (log

Summary statistics in Table 1 indicate a reduction in cardiac catheteri-

scale). The covariates in each model included a natural cubic spline to

zation laboratory activations and procedural volumes for STEMI in the

adjust for seasonal trends, an indicator variable for the year, categori-

AC period relative to baseline BC period. The overall median number

cal variable for the region, and an indicator variable for influenza epi-

of monthly cardiac catheterization laboratory activations decreased

demics (October–April). The COVID pandemic period was either

from 22 procedures in BC to 13 and 17 in March and April 2020,

coded as an indicator for BC/AC or a three-level categorical variable

respectively (Table 1, Figures 1 and S2). The reduction in STEMI acti-

(BC, March 2020, April 2020). The estimates are reported either as

vation volumes from BC was observed in all four regions (Figure 1).

percent change from baseline or incidence rate ratios (IRR) together

Nearly all participating sites experienced reductions in STEMI activa-

with the 95% confidence intervals (CI) and p-values. The analysis was

tion volumes in March 2020 relative to BC (Figure 1). The data also

conducted using R v4.0 in the Rstudio environment (Rstudio Inc.). No

indicate sizeable variations in STEMI activations from March to April

Institutional review board (IRB) approval was required to conduct this

2020, even within the same geographic region, with some STEMI pro-

survey of the cardiac catheterization laboratory during the COVID-19

grams returning to prepandemic levels (e.g., Iowa Heart, Christ Hospi-

Pandemic.

tal, Northwell, Swedish), some remaining suppressed (e.g., MHI, NY

TABLE 1

Median (Q1, Q3) for response variables by time period for participating STEMI programs (n)

Variable

Before COVID

March 20

April 20

STEMI activations, n = 18

22 (14, 28)

13 (7, 26)

17 (6, 24)

STEMI angiography, n = 12

12 (7, 17)

8 (4, 11)

8 (1, 14)

Primary PCI, n = 13
Median D2B, min, n = 12

8 (9, 15)

6 (4, 10)

7 (4, 11)

70 (61, 75)

70 (66, 95)

87 (57, 99)

Abbreviations: D2B, door to balloon time; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.

F I G U R E 1 Changes in cardiac
catheterization laboratory ST-elevation
myocardial infarction activations for each
program (gray lines) relative to their
respective mean BC volumes (Panel A)
and Changes in cardiac catheterization
laboratory ST-elevation myocardial
infarction activations according to
geographic regions (gray lines) relative to
their respective BC volumes (Panel B).
The purple line represents the overall
median. The band represents interquartile
ranges [Color figure can be viewed at
wileyonlinelibrary.com]
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by a decline in STEMI activations; when adjusted for the latter, the
estimated IRR = 0.07, 95%CI (−0.28, 0.41), p = .693.
Information on cardiac catheterization laboratory STEMI activations
leading to PPCI was available from 12 sites. The median volume of PPCI
fell from 8 procedures in the BC period to 6 and 7 in March and April
2020, respectively (Table 1 and Figure 3). The estimated reduction in
PPCI volumes in the AC period from BC was 20%, 95% CI: (11, 27),
p < .001. When controlled for STEMI activations, the estimated incidence
ratio relative to the BC period was IRR = 0.21(−0.06, 0.48), p = .123.
Information on D2B times was available from 12 sites. The data
indicated an increase in D2B (Table 1, Figure 4). The increase in D2B
times in AC relative to BC was 20%, 95% CI: (−0.2, 44), p = .052. On
average, D2B times in March 2020 relative to BC increased by 27%,
95% CI: (6, 52), p = .011 with no apparent change in D2B in April
2020; −11%, 95% CI: (−31, 13), p = .314.

4
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Our expanded analysis of the impact of COVID-19 Pandemic on
STEMI care has several key findings. First, the decline in cardiac catheterization laboratory activations for STEMI has persisted into April
2020, with some programs showing signs of recovery while others
remain significantly below their 2019 averages. Second, the number
of cardiac catheterization laboratory activations leading to coronary
F I G U R E 2 A dumbbell plot of Z-scores showing changes in
cardiac catheterization laboratory ST-elevation myocardial infarction
activations for each program. Units are standard deviations from their
BC means, for example, Z-score = 0 indicates that the volume at a
given month in 2020 is identical to the mean BC volume. A negative
Z-score indicates a decline in units of standard deviations from their
mean BC volumes. All programs saw a decline in March 2020 (Zscores marked by purple dots are all negative) with some recovering
in April to nearly 2019 volumes (e.g., Iowa, Christ Hospital, Northwell,
Swedish) and others either nearly unchanged (e.g., NY Presbyterian,
MHI, MGH) or worsening (Prairie, Delray, BHC, U Penn, San Diego).
BC, before COVID-19 [Color figure can be viewed at
wileyonlinelibrary.com]

angiography and PPCI has also declined during the Pandemic by 31%
and 18%, respectively. Third, the decline in STEMI metrics was seen in
all geographic areas included in our analysis, irrespective of COVID19 incidence, implementation of lockdown orders, and levels of testing. Finally, among patients who received PPCI, delays in reperfusion
were noted in March 2020 with improvements in April 2020.
COVID-19 has significantly impacted healthcare delivery in the
US and around the world. As hospital systems prepared to receive
COVID-19 patients, several measures were implemented that
restricted access to outpatient care, emergency room evaluations, and
diagnostic and therapeutic cardiac procedures deemed elective.
Unintended consequences of these directives have been docu-

Presbyterian, MGH) and others having volumes decline even further

mented.4-6,9,10 We have previously reported a 38% decline in cardiac

(e.g., BHC, UPenn, NYU Langone, Delray, San Diego; Figure 2).

catheterization laboratory activations for STEMI during the early

Relative to the BC period, the estimated average reduction in car-

phase of the COVID-19 Pandemic and highlighted the importance of

diac catheterization laboratory activations in the AC period was 29%,

continuous monitoring of this trend and need to investigate its causes

95% CI: (18, 38), p < .001. There was no apparent change in STEMI

as the pandemic effects are likely to be felt for most of 2020. To that

activation volumes in April 2020 relative to March 2020: IRR = 0.96,

end, we expanded our initial analysis from 9–18 STEMI programs

95% CI: (0.81, 1.14), p = .67.

(or healthcare systems) representative of the US, added more granular

Information on cardiac catheterization laboratory STEMI activa-

information regarding important metrics of STEMI care including utili-

tions leading to coronary angiography was available from 12 sites.

zation of coronary angiography, PPCI and D2B times, performed a

The median monthly volumes of angiographies for STEMI decreased

detailed geographic analysis in areas with different levels of COVID

from 12 in the BC period to 8 in both March and April 2020 (Table 1

testing and disease burden, and conducted a hospital-or healthcare

and Figure 3). The estimated reduction in AC volumes relative to BC

system-level analysis of trends during the Pandemic. Taken together,

was 34%, 95% CI: (12, 50), p = .005. The March 2020 volumes fell on

these observations suggest a negative, widespread, and persistent

average 20%, 95% CI: (0, 36), p = .053 from the BC period and the

impact on STEMI care during the COVID 19 pandemic in the US.

April volumes fell further by 30%, 95% CI: (5, 48), p = .022 relative to

The reduction in utilization of coronary angiography, PPCI, and

March. The reduction in angiography volumes appeared to be driven

delays in mechanical reperfusion suggest that even for patients who

5
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F I G U R E 3 Changes in cardiac
catheterization laboratory ST-elevation
myocardial infarction activations leading
to angiographies for each program (gray
lines) (Panel A) and leading to
percutaneous coronary intervention
(Panel B) relative to their respective
average BC volumes. The purple line
represents the overall median. The band
represents interquartile ranges. BC, before
COVID-19 [Color figure can be viewed at
wileyonlinelibrary.com]

F I G U R E 4 Changes in median door to
balloon times for each program (gray lines)
relative to their respective average BC
volumes. The purple line represents the
overall median. The band represents
interquartile ranges. BC, before COVID19 [Color figure can be viewed at
wileyonlinelibrary.com]

present to the healthcare system, processes of care might have chan-

speculative and may include (a) overwhelmed emergency medical sys-

ged during the Pandemic. Although some have advocated for

tems (EMS), (b) changes in STEMI pathways to facilitate testing in the

increased use of pharmacological (thrombolytic) reperfusion or

emergency department with cancellations of direct transfers to the

11

the American College of Cardiology

cardiac catheterization laboratory, (c) increased used of imaging,

(ACC) and Society for Cardiovascular Angiography and Interventions

including cardiac CT and echocardiography, to triage STEMI patients

(SCAI) continue to recommend PPCI for STEMI patients.12 In fact, of

suspected of having COVID,13 (d) late presentations, outside the ther-

the programs surveyed for this analysis, only three reported using

apeutic window for mechanical reperfusion, and (e) insufficient access

fibrinolytic therapy with very few patients treated (<5 per year). None

to personnel protective equipment.

pharmacoinvasive strategies,

of them reported using them preferentially during the COVID-19 Pan-

The finding of similar reductions in STEMI activations in various

demic. The reasons for these reductions and treatment delays remain

geographic areas within the US with different COVID-19 disease

6
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burden suggests that overwhelmed EMS systems alone are unlikely to

Houman Khalili

explain these declines. Avoidance of the medical system due to fear

Keshav R. Nayak

of contracting COVID-19, restricted access to primary care physicians

Mauricio G. Cohen

and emergency departments, and STEMI misdiagnosis are likely to

Timothy D. Henry
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play a role.14 Of note, some healthcare systems seem to be
rebounding from their March 2020 declines faster than others and

RE FE RE NCE S

may provide some clues as to what is needed to revert these trends.
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For example, Christ Hospital in Cincinnati, OH, conducted an extensive media and public relations campaign in late March to alert
patients about the importance of timely medical care. In April 2020,
their number of STEMI activations was back to 2019 levels. More
information is needed to understand the drivers of and potential solutions to these negative trends in STEMI care.

4.1
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Limitations

Our study has important strengths, including 16 months of continuous
STEMI metrics in 18 large hospitals or healthcare systems representative of diverse areas of the US, but also important limitations. First,
given the observational study design, our results are hypothesisgenerating regarding the potential mechanisms leading to a reduction
in STEMI metrics. Second, we were unable to provide individualpatient data, including demographic, angiographic, and treatment data.
Third, we included STEMI hospitals and healthcare systems that may
have different configurations (spoke and hub), transfer, and time to
treatment protocols. We provided aggregate data for some STEMI
metrics but lack granular information on transfer times and other
aspects of STEMI care.
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The COVID-19 Pandemic has had a negative, widespread, and persistent impact on STEMI care in the US. Efforts to educate the public on
the importance of timely care and to maintain unrestricted access to
emergency medical care are needed to overcome these trends.
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